J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug
Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.